Table 1
Baseline demographic and clinical characteristics.
Table 2
Laboratory results for patients treated without statins during the follow-up period.
| Parameter | Baseline | After 6 months of treatment | P value |
|---|---|---|---|
| 25 OH-vitamin D level (ng/dl) – mean (SD) | 17,3 (7,7) | 43,2 (9,8) | <0,0001* |
| Total cholesterol (mg/dl) – mean (IQR) | 186,5 (171-213) | 185,5 (173-210) | <0,0001** |
| HDL cholesterol (mg/dl) – mean(IQR) | 54,5 (46-62) | 54,5 (47-63,3) | 0,0697** |
| LDL cholesterol (mg/dl) – mean (IQR) | 113 (90-127) | 110 (90-125) | <0,0001** |
| Triglycerides (mg/dl) – mean (IQR) | 91,5 (66-113) | 93 (67-115) | 0,9578** |
Figure 1
Evolution of serum level of total cholesterol and LDL cholesterol in patients who did not receive statin treatment during the follow-up period. (LDL=low density lipoproteins, IQR-interquartile range)
Table 3
Differences in laboratory test results during the follow-up period for the two study groups
| 6 months differences | Statin group (n=100) | Without statin group (n=56) | P value |
|---|---|---|---|
| 25 OH-vitamin D level (ng/dl) – medie (IQR) | +23,9 (+19,4 - +29,3) | +29,2 (+19,9- +29,7) | 0,0139* |
| Total Cholesterol (mg/dl) – mean (IQR) | -2,0 (-5 - -1) | -2,0 (-4 – 0,0) | 0,2491* |
| HDL cholesterol (mg/dl) – mean (IQR) | +1 (0 - +1) | 0 (0 - +1) | 0,0168* |
| LDL cholesterol (mg/dl) – mean (IQR) | -2,0 (-4 - -1) | -1 (-2,8 - 0) | 0,0013* |
| Triglycerides (mg/dl) – mean (IQR) | -1 (-2 - 0) | -0,5 (-1 - +1) | 0,0105* |